"Designing Growth Strategies is in our DNA"

Chronic Obstructive Pulmonary Disease Drugs Market Size, Share and Global Trend By Drug Class (Bronchodilators, Steroids, Combination drugs), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), and Geography Forecast till 2026

Region : Global | Report ID: FBI101176 | Status : Ongoing

 

KEY MARKET INSIGHTS

In February 2019, FDA approved the use of Yupelri inhalation solution manufactured by Mylan for patients suffering from chronic obstructive pulmonary disease. According to the World health Organisation (WHO), chronic obstructive pulmonary disease (COPD) is a type of life-threatening lung disorder that disrupts the lung airflow and interferes with normal breathing.

The major factors that cause COPD are exposure to cigarette smoke, air pollution, chemical fumes or dust, rare genetic condition, among others. Recent studies (2018) published in The Lancet Respiratory Medicine, revealed that permanent lung damage caused due to COPD starts even before the patient experience any symptoms.

To gain extensive insights into the market, Request for Customization


The Global Burden of Disease Study (2016) performed by the Institute of Health Metrics and Evaluation, reported 251 million incidences of COPD globally. According to WHO, globally approximate 200 million people were diagnosed with COPD in the year 2016. Urbanization in developing countries in the Asia Pacific exposes the population to various forms of lung irritants that could be a major risk factor to cause COPD.

The World Health Organisation (WHO) states that the most common cause of COPD is exposure to tobacco smoke both via first hand and second-hand smoking. This global increase in the prevalence of COPD is expected to drive the COPD drugs market growth during the forecast period.


The high economic burden in the treatment of COPD is expected to harm the growth of the global COPD drugs market. Centre for Disease Control and Prevention (CDCP) attributed that the cost related to COPD in the US were 32.1 $ billion in the year 2010 and is projected to increase to 49 billion by the year 2020.


Key Players Covered


Key players operating in the global chronic obstructive pulmonary disease drugs market are Mylan N.V., GlaxoSmithKline plc., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Pharmaceuticals LP, and others.


SEGMENTATION






















SEGMENTATION



 DETAILS



By Drug Class



· Bronchodilators


· Steroids


· Combination drugs


· Others



By Distribution Channel



· Hospital pharmacy


· Retail pharmacy


· Online pharmacy



By Geography



· North America (USA and Canada)


· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


· Latin America (Brazil, Mexico and Rest of Latin America)


· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



 


At present, among drug class segment, bronchodilators are considered to hold the major share of the COPD drugs market due to the increased efficacy of the drug class that could lead to a rise in adoption of the therapy globally.


Key Insights



  • Pipeline analysis

  • Prevalence of COPD

  • Overview of the regulatory scenario for key countries

  • Pricing analysis of key market players

  • Key collaborations of companies


Regional Analysis


The global COPD drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global COPD drugs market owing exponentially increasing air pollution, the rapid pace of industrialization, and the adoption of a sedentary lifestyle. Moreover, growth in the smoking population and lack of awareness of COPD is expected to raise the prevalence of the disease, resulting in increased adoption of COPD drugs. According to The Lung Association, COPD is prevalent in men and women and is the sixth most common factor of hospitalization in women and fourth most in men in Canada. The Asia Pacific, Middle East, and Africa also hold huge potential for growth of the global COPD drugs owing to the rising prevalence of respiratory distress conditions. For instance, the data published by the World health organization (WHO) states that more than 90% of death due to COPD happen in low and middle-income countries. Rapid urbanization that causes an increase in air pollution provides amplifies predisposition to acquire respiratory diseases like COPD, hence providing lucrative growth opportunities for COPD drugs market in these regions.


COPD Drugs Industry Developments





  • In July 2018, FDA advisory committee voted against the approval of GSK’s mepolizumab (Nucala) as add on treatment for patients suffering from COPD.
  • In September 2017, TRELEGY ELLIPTA developed by GSK in collaboration with Innoviva was approved by the U.D FDA for use in patients suffering from COPD.
  • In September 2014, Boehringer Ingelheim received U.S FDA approval for SPIRIVA RESPIMAT for long term treatment of bronchospasm associated with COPD.
  • In January 2019, The European Commission approves Bevespi Aerosphere (glycopyrronium/formoterol fumarate) developed by AstraZeneca indicated for adults with COPD.

Chronic Obstructive Pulmonary Disease Drugs Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

SUANFARMA
Bio-Rad
Logo_Merck_KGaA_2015
baxter
Sedana-Cyan-Black-Tag

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X